



Abbott Laboratories (Pakistan) Limited

City Office: 8th Floor Faysal House
ST-02, Sharah-e-Faisal, Karachi-75350
P.O. Box 7229 Karachi 74400
Tel : (92-21) 111-Abbott (111-222-688)
Tel : (92-21) 32799018-19
Fax : (92-21) 32800244

Abbott Laboratories (Pakistan) Limited

Registered Office: Opp. Radio Pakistan
Transmission Centre, Hyderabad Road,
Landhi, Karachi-75120
P.O. Box 7229, Karachi 74400
Tel : (92-21) 35069748-49
Fax : (92-21) 35001903

February 24th, 2025

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi

Subject: **Additional Information to Financial Results for the Year Ended 31st December 2024**

Dear Sir / Madam

This is further to our letter dated 20th February 2025, please enclosed additional information to the financial results for the year ended December 31st, 2024, duly approved by the Board of Directors in their meeting held on 20th February 2025.

You may please inform the TRE Certificate Holders of the Exchange accordingly.

Yours faithfully,
ABBOTT LABORATORIES (PAKISTAN) LIMITED

MUHAMMAD USAMA JAMIL
COMPANY SECRETARY

CC: Executive Director / HOD
Securities Exchange Commission of Pakistan,
NIC Building, 63 Jinnah Avenue
Blue Area, Islamabad

Additional Registrar of Companies
Securities and Exchange Commission of Pakistan
Company Registration Office
4th Floor, SLIC Building No. 2
Wallace Road
Karachi

ABBOTT LABORATORIES (PAKISTAN) LIMITED
STATEMENT OF FINANCIAL POSITION
AS AT DECEMBER 31, 2024

		2024	2023			2024	2023
		Note	(Rupees '000)			Note	(Rupees '000)
<u>EQUITY AND LIABILITIES</u>				<u>ASSETS</u>			
SHARE CAPITAL AND RESERVES				NON-CURRENT ASSETS			
Authorised capital	3	<u>2,000,000</u>	<u>2,000,000</u>	Property, plant and equipment	11	14,252,797	13,375,186
Issued, subscribed and paid-up capital	4	979,003	979,003	Intangible assets	12	1,250	12,678
Reserves - capital		1,750,481	1,437,162	Long-term loans and advances	13	114,226	95,423
- revenue		20,995,152	15,821,181	Long-term deposits		7,513	7,513
Total equity		<u>23,724,636</u>	<u>18,237,346</u>	Long-term prepayments		13,710	3,427
				Total non-current assets		<u>14,389,496</u>	<u>13,494,227</u>
NON-CURRENT LIABILITIES				CURRENT ASSETS			
Deferred taxation - net	5	1,052,587	519,569	Stores and spares	14	529,619	462,670
Staff retirement benefits	6	1,184,179	1,049,089	Stock-in-trade	15	10,694,515	12,826,865
Lease liabilities	7	29,545	52,228	Trade debts	16	2,982,679	1,649,512
Total non-current liabilities		<u>2,266,311</u>	<u>1,620,886</u>	Loans and advances	17	938,021	472,735
				Trade deposits and short-term prepayments	18	283,813	320,399
CURRENT LIABILITIES				Other receivables	19	1,182,530	2,044,254
Trade and other payables	8	10,951,662	15,091,467	Taxation - net		468,136	386,071
Unclaimed dividends		63,715	64,676	Cash and cash equivalents	20	6,182,349	5,036,712
Unpaid dividends		-	1,029,503	Total current assets		<u>23,261,662</u>	<u>23,199,218</u>
Current maturity of lease liabilities	7	22,683	105,990				
Provisions	9	622,151	543,577				
Total current liabilities		<u>11,660,211</u>	<u>16,835,213</u>				
CONTINGENCIES AND COMMITMENTS							
	10						
TOTAL EQUITY AND LIABILITIES		<u>37,651,158</u>	<u>36,693,445</u>	TOTAL ASSETS		<u>37,651,158</u>	<u>36,693,445</u>

The annexed notes 1 to 43 form an integral part of these financial statements.

Chief Executive Officer

Director

Chief Financial Officer

ABBOTT LABORATORIES (PAKISTAN) LIMITED
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED DECEMBER 31, 2024

		2024	2023
	Note (Rupees '000)
CASH FLOWS FROM OPERATING ACTIVITIES			
Cash generated from operations	30	8,356,459	3,176,942
Income tax paid		(3,325,706)	(2,311,498)
Minimum tax differential paid		(105,530)	(525,397)
Final taxes paid		-	(22,505)
Long-term loans and advances - net		(18,803)	(28,914)
Long-term prepayments - net		(10,283)	(2,781)
Contributions to staff retirement benefit funds	6.7	(300,648)	(275,552)
Net movement in provisions		78,574	(72,599)
Net cash generated from / (used in) operating activities		<u>4,674,063</u>	<u>(62,304)</u>
CASH FLOWS FROM INVESTING ACTIVITIES			
Additions to property, plant and equipment		(3,022,082)	(3,074,518)
Sale proceeds from disposal of operating fixed assets	11.5	181,547	139,846
Interest income		472,177	735,631
Net cash used in investing activities		<u>(2,368,358)</u>	<u>(2,199,041)</u>
CASH FLOWS FROM FINANCING ACTIVITIES			
Bank charges paid	27	(11,875)	(8,115)
Interest portion of lease liabilities paid	7.1	(11,739)	(22,175)
Principal portion of lease liabilities paid		(105,990)	(89,069)
Dividends paid	31	(1,030,464)	(1,374,413)
Net cash used in financing activities		<u>(1,160,068)</u>	<u>(1,493,772)</u>
Net increase / (decrease) in cash and cash equivalents		<u>1,145,637</u>	<u>(3,755,117)</u>
Cash and cash equivalents at the beginning of the year		5,036,712	8,791,829
Cash and cash equivalents at the end of the year	20	<u>6,182,349</u>	<u>5,036,712</u>

The annexed notes 1 to 43 form an integral part of these financial statements.

Chief Executive Officer

Director

Chief Financial Officer

ABBOTT LABORATORIES (PAKISTAN) LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED DECEMBER 31, 2024

	Issued, subscribed and paid-up capital	Reserves				Total	Total equity
		Capital reserves		Revenue reserves			
		Reserve arising on merger	Share based compensation reserve	General reserve	Un-appropriated profit		
(Rupees '000)							
Balance as at January 01, 2023	979,003	46,097	1,012,542	5,338,422	9,729,965	16,127,026	17,106,029
Employee benefit cost under IFRS 2 - 'Share-based payments'	-	-	378,523	-	-	378,523	378,523
Total comprehensive income for the year ended December 31, 2023							
Profit for the year	-	-	-	-	261,777	261,777	261,777
Other comprehensive income for the year - net of tax	-	-	-	-	491,017	491,017	491,017
Total comprehensive income for the year	-	-	-	-	752,794	752,794	752,794
Balance as at December 31, 2023	979,003	46,097	1,391,065	5,338,422	10,482,759	17,258,343	18,237,346
Balance as at January 01, 2024	979,003	46,097	1,391,065	5,338,422	10,482,759	17,258,343	18,237,346
Employee benefit cost under IFRS 2 - 'Share-based payments'	-	-	313,319	-	-	313,319	313,319
Total comprehensive income for the year ended December 31, 2024							
Profit for the year	-	-	-	-	5,234,233	5,234,233	5,234,233
Other comprehensive loss for the year - net of tax	-	-	-	-	(60,262)	(60,262)	(60,262)
Total comprehensive income for the year	-	-	-	-	5,173,971	5,173,971	5,173,971
Balance as at December 31, 2024	979,003	46,097	1,704,384	5,338,422	15,656,730	22,745,633	23,724,636

The annexed notes 1 to 43 form an integral part of these financial statements.

Chief Executive Officer

Director

Chief Financial Officer